Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
20 févr. 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Fractyl Health Announces Pricing of Initial Public Offering
01 févr. 2024 20h08 HE
|
Fractyl Health, Inc.
Fractyl Health (Nasdaq: GUTS), announces pricing of initial public offering.
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
05 janv. 2024 07h48 HE
|
Fractyl Health, Inc.
FRACTYL HEALTH ANNOUNCES NOMINATION OF RJVA-001 AS FIRST CLINICAL CANDIDATE IN ITS REJUVA® GLP-1 GENE THERAPY PLATFORM
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure
14 déc. 2023 05h45 HE
|
Fractyl Health, Inc.
Fractyl Health Announces New Pooled Analysis From Revita Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance without Gain
Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting
11 déc. 2023 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health presented preclinical findings from its Rejuva® gene therapy platform at the WCIRD23 Annual Meeting.
Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity
16 nov. 2023 08h28 HE
|
Fractyl Health, Inc.
FRACTYL HEALTH EXPANDS LANDMARK ACADEMIC-INDUSTRY COLLABORATION TO STUDY MECHANISMS UNDERLYING GLP-1-BASED PANCREATIC GENE THERAPY FOR TYPE 2 DIABETES AND